{"id":530,"date":"2019-02-25T09:00:00","date_gmt":"2019-02-25T09:00:00","guid":{"rendered":"https:\/\/isosolution-v2.staging.xiyx.ai\/news\/concomitant-177lu-dotatate-and-capecitabine-therapy-in-malignant-paragangliomas\/"},"modified":"2019-02-25T09:00:00","modified_gmt":"2019-02-25T09:00:00","slug":"concomitant-177lu-dotatate-and-capecitabine-therapy-in-malignant-paragangliomas","status":"publish","type":"iso_news","link":"https:\/\/isosolution-v2.staging.xiyx.ai\/es\/news\/concomitant-177lu-dotatate-and-capecitabine-therapy-in-malignant-paragangliomas\/","title":{"rendered":"Concomitante 177Lu-DOTATATE y terapia de capecitabina en paragangliomas malignos"},"content":{"rendered":"<p>El papel de la terapia concomitante del receptor de p\u00e9ptidos radion\u00faclidos (PRRT) y la terapia de capecitabina ha mostrado beneficio en los tumores gastroenteropancre\u00e1ticos neuroendocrinos. Sin embargo, falta informaci\u00f3n sobre su papel en los pacientes paraganglioma (PGL). El objetivo de este estudio fue evaluar el papel de la capecitabina combinada y 177Lu-DOTATATE en pacientes malignos de PGL. <a href=\"https:\/\/isosolutions.com\/concomitant-177lu-dotatate-and-capecitabine-therapy-in-malignant-paragangliomas\/\"><span aria-label=\"Continuar leyendo Terapia concomitante 177Lu-DOTATATE y capecitabina en paragangliomas malignos\">(m\u00e1s...)<\/span><\/a><\/p>\n<\/p><\/div>\n<p>Etiquetas: <a href=\"https:\/\/isosolutions.com\/news-tag\/capecitabine\/\" rel=\"tag\">Capecitabina<\/a> <a href=\"https:\/\/isosolutions.com\/news-tag\/lu-177\/\" rel=\"tag\">Lu-177<\/a> <a href=\"https:\/\/isosolutions.com\/news-tag\/paraganglioma\/\" rel=\"tag\">Paraganglioma<\/a><\/p>\n<\/p><\/div>","protected":false},"excerpt":{"rendered":"<p>The role of concomitant peptide receptor radionuclide therapy (PRRT) and capecitabine therapy has shown benefit in gastroenteropancreatic neuroendocrine tumors. However, data reporting its role in\u2026<\/p>","protected":false},"featured_media":558,"template":"","iso_news_section":[43],"class_list":["post-530","iso_news","type-iso_news","status-publish","has-post-thumbnail","hentry"],"_links":{"self":[{"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/es\/wp-json\/wp\/v2\/iso_news\/530","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/es\/wp-json\/wp\/v2\/iso_news"}],"about":[{"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/es\/wp-json\/wp\/v2\/types\/iso_news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/es\/wp-json\/wp\/v2\/media\/558"}],"wp:attachment":[{"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/es\/wp-json\/wp\/v2\/media?parent=530"}],"wp:term":[{"taxonomy":"iso_news_section","embeddable":true,"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/es\/wp-json\/wp\/v2\/iso_news_section?post=530"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}